MAP focused on current and emerging approaches in precision oncology, highlighted successes and challenges, and proposed potential solutions in clinical research and practice.

Our globally recognised experts in the field attracted attendees for three days of discussions on discoveries in precision medicine, technologies for cancer profiling, mechanisms driving tumour expansion, metastatic dissemination, clonal evolution, and biomarker-driven development of targeted therapeutics.

The 2024 RoadMAP to the Clinic focused on “The use of AI for drug development / precision medicine.” This special day featured lectures and panel discussions involving investigators, regulatory and methodological experts, industry and patient representatives on the burning topics of deploying AI at scale, tackling regulatory and ethical aspects of AI implementation in clinical trials, and examining the opportunities and challenges of AI for research and practice.

The MAP Congress is the result of a solid partnership among Cancer Research UK (CRUK), the European Society for Medical Oncology (ESMO), and Unicancer, all committed to offering the best care to people with cancer worldwide through oncology education and research.